Ovarian cancer information, including diagnostics, treatments, side effects and further resources for oncologists

Oncological Disease » Ovarian Cancer »

Tuesday, 13 May, 2008

Browse by Topic

» Brain Tumor » Breast Cancer » Cervical Cancer » Colorectal Cancer » Endometrial Cancer » Gastrointestinal Cancer » Genitourinary Cancer » Leukemia » Lung Cancer » Ovarian Cancer

Hot Topic

New Ovarian Cancer Drug Trial Under Way
Sept 7, 2007
Ovarian cancer patients whose cancer has become resistant to traditional chemotherapy can now log-on to a new Web site to learn about a trial of a new drug, phenoxodiol.

Other Articles from Touch

Long-term Survival Advantage for Recurrent Ovarian Cancer Patients Receiving Pegylated Liposomal Doxorubicin

Ovarian Cancer in Relapse: Medical Management Approaches

The Role of Surgery in the Treatment of Gynecologic Cancers – A Shifting Paradigm

Newly FDA-approved drugs

Gemzar (gemcitabine HCl) for Injection
Company: Eli Lilly and Company
New Indication Approved: July 14, 2006
Approvals process

Treatment for: Ovarian Cancer
Gemzar in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.

Medical therapy of advanced malignant epithelial tumours of the ovary

Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study

A systematic overview of chemotherapy effects in ovarian cancer

Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer

Triplet combination of gemcitabine, carboplatin, and paclitaxel in previously treated, relapsed ovarian and peritoneal carcinoma: an experience in Taiwan

Focus on

Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer

Evaluation of metronomic chemotherapy as salvage therapy in a young patient with advanced, platinum resistant, ovarian carcinoma and bad performance status.

Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer

Due to the paucity of published phase I data on the 3-weekly experimental schedule used, an early safety analysis was planned.

Mismatch repair and treatment resistance in ovarian cancer

The aim of this study is to determine the frequency of mismatch repair (MMR) inactivation in ovarian cancer and its association with resistance to platinum-based chemotherapy.

Guidelines Watch

A round up of the latest Clinical Guidelines from the National Guideline Clearinghouse (NGC)

First-line chemotherapy for postoperative patients with stage II, III or IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cance

Screening for ovarian cancer: recommendation statement

Upcoming Events

Cancer Epigenetics
28 - 31 May 2008
Boston Park Plaza Hotel, Boston, USA

2008 ASCO Annual Meeting
30 May - 03 Jun 2008
McCormick Place, Chicago, USA

ASCO Annual Meeting
30 May - 03 Jun 2008
McCormick Place, Chicago, USA

Terms & Conditions | Privacy Statement|

Articles :	a b c d e f g h i j k l m n o p q r s t u v w x y z
Companies :	a b c d e f g h i j k l m n o p q r s t u v w x y z
Events :	a b c d e f g h i j k l m n o p q r s t u v w x y z
Keywords :	a b c d e f g h i j k l m n o p q r s t u v w x y z
Specialities :	Brain Tumor Breast Cancer Cervical Cancer Colorectal Cancer Endometrial Cancer Gastrointestinal Cancer Genitourinary Cancer Leukemia Lung Cancer Ovarian Cancer
Other Touch Group sites:	Cardiology - Endocrine Disease - Oncological Disease - Gastroenterology - Respiratory Disease